Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
Autor: | Ryan, Christine E., Lampson, Benjamin L., Tyekucheva, Svitlana *, Hackett, Liam R. *, Ren, Yue *, Shupe, Samantha J. *, Fernandes, Stacey M. *, Crombie, Jennifer L. *, Ng, Samuel *, Kim, Austin I., Ahn, Inhye E., Weinstock, Matthew J, Pazienza, Samantha *, Montegaard, Josie S. *, Patterson, Victoria *, Jacobson, Caron A., LaCasce, Ann S., Armand, Philippe, Fisher, David C. *, Arnason, Jon E., Lo, Steve *, Olszewski, Adam *, Brown, Jennifer R., Davids, Matthew S. |
---|---|
Zdroj: | In Blood 15 November 2022 140 Supplement 1:837-838 |
Databáze: | ScienceDirect |
Externí odkaz: |